Eisai and Biogen Launch At-Home Alzheimer's Injection in U.S. Market

Key Facts

1Eisai and Biogen launched LEQEMBI IQLIK, a weekly subcutaneous injection for early Alzheimer's, in the U.S.

In a move reflecting the accelerating pace of healthcare innovation, Eisai and Biogen have officially launched LEQEMBI IQLIK in the United States. This weekly subcutaneous injection is designed for patients with early Alzheimer's disease, including mild cognitive impairment or mild dementia. The new delivery method aims to simplify treatment by providing a convenient at-home option, replacing the need for clinical intravenous infusions.

This expansion of the product delivery method is expected to increase market reach and improve patient adherence to the treatment regimen. Per market data, the stock of Eisai (4523.T) stood at 4902 JPY at the close of August 21, 2026, having fluctuated between a day high of 4971 JPY and a day low of 4875 JPY during that session.

Strategically, the shift toward at-home administration marks a significant milestone for Eisai and Biogen in the competitive neurology market. With the instrument price at 4902 JPY as of the August 21, 2026 close, investors will be monitoring how this increased convenience impacts drug adoption rates in the U.S. market over the coming months.

Sources:

Investing.com India